<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03811600</url>
  </required_header>
  <id_info>
    <org_study_id>2019-A00029-48</org_study_id>
    <nct_id>NCT03811600</nct_id>
  </id_info>
  <brief_title>Exosomes Implication in PD1-PD-L1 Activation in OSAS</brief_title>
  <acronym>ExoSAS</acronym>
  <official_title>Exosomes Implication in PD1-PD-L1 Pathway Activation in Obstructive Sleep Apnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Angers</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Angers</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An increased occurrence of cancer associated mortality has been described in patients with
      Obstructive Sleep Apnea Syndrome (OSAS). This association might be partially explained by an
      impaired cellular immune response that has been described in OSAS. Is has been suggested that
      OSAS impact immune cells by upregulation of the PD-1/PD-L1 pathway. Exosomes are small
      membrane vesicles released by numerous cells in the bloodstream. Exosomes have been shown to
      be implicated in cancer cells proliferation via a PD-1/PD-L1 pathway activation.

      This study will evaluate exosomal PD-1/PD-L1 expression in patients with OSAS as compared to
      controls and will further investigate their impact on immune cells function and proliferation
      capacities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>exosomal PD1 expression</measure>
    <time_frame>at baseline</time_frame>
    <description>Peripheral blood (≈20 ml) will be collected from non-OSAS or OSAS subjects on EDTA-coated tubes. Exosomes will be isolated by centrifugation. For detecting exosome-associated surface proteins by flow cytometry, exosomes will be first captured on magnetic beads. The bead/exosome complexes will be then co-incubated with the labeled detection antibodies, either anti-PD1. Next, the complexes will be washed 3x resuspended in 300uL of PBS for antigen detection by flow cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>exosomal PD-L1 expression</measure>
    <time_frame>at baseline</time_frame>
    <description>Peripheral blood (≈20 ml) will be collected from non-OSAS or OSAS subjects on EDTA-coated tubes. Exosomes will be isolated by centrifugation. For detecting exosome-associated surface proteins by flow cytometry, exosomes will be first captured on magnetic beads. The bead/exosome complexes will be then co-incubated with the labeled detection antibodies, either anti-PD-L1. Next, the complexes will be washed 3x resuspended in 300uL of PBS for antigen detection by flow cytometry.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Sleep Apnea Syndromes, Obstructive</condition>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>OSAS patients</arm_group_label>
    <description>45 patients investigated for suspected OSAS with an apnea hypopnea index ≥15 per hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non OSAS patients</arm_group_label>
    <description>45 patients investigated for suspected OSAS with an apnea hypopnea index &lt;15 per hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PD1/PD-L1 exosomal expression</intervention_name>
    <description>exosomal PD1/PD-L1 expression</description>
    <arm_group_label>Non OSAS patients</arm_group_label>
    <arm_group_label>OSAS patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma and serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients investigated by sleep recording for suspected OSAS will be included in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients requiring a sleep recording for suspected OSAS

        Exclusion Criteria:

          -  Préviously treated OSAS

          -  Cancer past history

          -  Pregnant women

          -  Cognitif impairment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wojciech Trzepizur, MD PhD</last_name>
    <phone>+33680575272</phone>
    <phone_ext>+33</phone_ext>
    <email>wotrzepizur@chu-angers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Laboratoire du Sommeil, Département de Pneumologie, CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <zip>49100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wojciech Trzepizur, MD</last_name>
      <phone>0680575272</phone>
      <phone_ext>+33</phone_ext>
      <email>wotrzepizur@chu-angers.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 15, 2019</study_first_submitted>
  <study_first_submitted_qc>January 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2019</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

